FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2218348537> ?p ?o ?g. }

• W2218348537 endingPage "e117" @default.
• W2218348537 startingPage "e117" @default.
• W2218348537 abstract "BackgroundHepatitis C virus (HCV) infection can lead to increased insulin resistance, but the dynamics of insulin resistance in HCV-infected patients receiving pegylated interferon plus ribavirin remain elusive.MethodsThe prospective study enrolled HCV-infected patients who received pegylated interferon plus ribavirin. Patients were classified according to the attainment of sustained virological response (SVR). The insulin resistance was measured by homeostatic model assessment-insulin resistance (HOMA-IR). The change of HOMA-IR at baseline, the end-of-treatment, and 24-weeks after the end-of-treatment was compared in patients who achieved sustained virologic response (SVR) or not.ResultsA total of 65 patients participated in this study and 46 (71%) of them achieved SVR. Overall, The HOMA-IR changed significantly during antiviral therapy, with the median values (interquartile range, IQR) of 3.7 (1.6-10.0) prior to treatment, 1.5 (0.8-2.9) at the end, and 1.6 (0.9-3.1) 24 weeks after completion of therapy. However, only patients who achieved SVR had significant off-therapy reduction of HOMA-IR, with the median values of 1.3 (IQR, 0.7-2.6) 24 weeks off therapy and 3.6 (IQR, 1.5-9.9) at baseline, respectively (P < .0001). In those without SVR, the HOMA-IR measured 24 weeks after treatment completion (median, 2.2; IQR, 1.9-4.7) did not differ from their baseline (median, 3.9; IQR, 2.2-10.0; P = .5).ConclusionDual therapy with pegylated interferon plus ribavirin ameliorated IR in HCV-infected patients, but the off-therapy improvement of IR was limited to those who attained SVR. BackgroundHepatitis C virus (HCV) infection can lead to increased insulin resistance, but the dynamics of insulin resistance in HCV-infected patients receiving pegylated interferon plus ribavirin remain elusive. Hepatitis C virus (HCV) infection can lead to increased insulin resistance, but the dynamics of insulin resistance in HCV-infected patients receiving pegylated interferon plus ribavirin remain elusive. MethodsThe prospective study enrolled HCV-infected patients who received pegylated interferon plus ribavirin. Patients were classified according to the attainment of sustained virological response (SVR). The insulin resistance was measured by homeostatic model assessment-insulin resistance (HOMA-IR). The change of HOMA-IR at baseline, the end-of-treatment, and 24-weeks after the end-of-treatment was compared in patients who achieved sustained virologic response (SVR) or not. The prospective study enrolled HCV-infected patients who received pegylated interferon plus ribavirin. Patients were classified according to the attainment of sustained virological response (SVR). The insulin resistance was measured by homeostatic model assessment-insulin resistance (HOMA-IR). The change of HOMA-IR at baseline, the end-of-treatment, and 24-weeks after the end-of-treatment was compared in patients who achieved sustained virologic response (SVR) or not. ResultsA total of 65 patients participated in this study and 46 (71%) of them achieved SVR. Overall, The HOMA-IR changed significantly during antiviral therapy, with the median values (interquartile range, IQR) of 3.7 (1.6-10.0) prior to treatment, 1.5 (0.8-2.9) at the end, and 1.6 (0.9-3.1) 24 weeks after completion of therapy. However, only patients who achieved SVR had significant off-therapy reduction of HOMA-IR, with the median values of 1.3 (IQR, 0.7-2.6) 24 weeks off therapy and 3.6 (IQR, 1.5-9.9) at baseline, respectively (P < .0001). In those without SVR, the HOMA-IR measured 24 weeks after treatment completion (median, 2.2; IQR, 1.9-4.7) did not differ from their baseline (median, 3.9; IQR, 2.2-10.0; P = .5). A total of 65 patients participated in this study and 46 (71%) of them achieved SVR. Overall, The HOMA-IR changed significantly during antiviral therapy, with the median values (interquartile range, IQR) of 3.7 (1.6-10.0) prior to treatment, 1.5 (0.8-2.9) at the end, and 1.6 (0.9-3.1) 24 weeks after completion of therapy. However, only patients who achieved SVR had significant off-therapy reduction of HOMA-IR, with the median values of 1.3 (IQR, 0.7-2.6) 24 weeks off therapy and 3.6 (IQR, 1.5-9.9) at baseline, respectively (P < .0001). In those without SVR, the HOMA-IR measured 24 weeks after treatment completion (median, 2.2; IQR, 1.9-4.7) did not differ from their baseline (median, 3.9; IQR, 2.2-10.0; P = .5). ConclusionDual therapy with pegylated interferon plus ribavirin ameliorated IR in HCV-infected patients, but the off-therapy improvement of IR was limited to those who attained SVR. Dual therapy with pegylated interferon plus ribavirin ameliorated IR in HCV-infected patients, but the off-therapy improvement of IR was limited to those who attained SVR." @default.
• W2218348537 created "2016-06-24" @default.
• W2218348537 creator A5009281267 @default.
• W2218348537 creator A5020095413 @default.
• W2218348537 creator A5025120257 @default.
• W2218348537 creator A5042965323 @default.
• W2218348537 creator A5078397604 @default.
• W2218348537 creator A5091805248 @default.
• W2218348537 date "2015-07-01" @default.
• W2218348537 modified "2023-10-17" @default.
• W2218348537 title "Change of Insulin Resistance in Hepatitis C Virus-infected Patients Receiving Pegylated Interferon Plus Ribavirin" @default.
• W2218348537 doi "https://doi.org/10.1016/j.cgh.2015.04.148" @default.
• W2218348537 hasPublicationYear "2015" @default.
• W2218348537 type Work @default.
• W2218348537 sameAs 2218348537 @default.
• W2218348537 citedByCount "0" @default.
• W2218348537 crossrefType "journal-article" @default.
• W2218348537 hasAuthorship W2218348537A5009281267 @default.
• W2218348537 hasAuthorship W2218348537A5020095413 @default.
• W2218348537 hasAuthorship W2218348537A5025120257 @default.
• W2218348537 hasAuthorship W2218348537A5042965323 @default.
• W2218348537 hasAuthorship W2218348537A5078397604 @default.
• W2218348537 hasAuthorship W2218348537A5091805248 @default.
• W2218348537 hasConcept C119060515 @default.
• W2218348537 hasConcept C126322002 @default.
• W2218348537 hasConcept C203014093 @default.
• W2218348537 hasConcept C2522874641 @default.
• W2218348537 hasConcept C2776408679 @default.
• W2218348537 hasConcept C2776455275 @default.
• W2218348537 hasConcept C2776461080 @default.
• W2218348537 hasConcept C2776999253 @default.
• W2218348537 hasConcept C2777391703 @default.
• W2218348537 hasConcept C2779306644 @default.
• W2218348537 hasConcept C2780040827 @default.
• W2218348537 hasConcept C71924100 @default.
• W2218348537 hasConcept C90924648 @default.
• W2218348537 hasConceptScore W2218348537C119060515 @default.
• W2218348537 hasConceptScore W2218348537C126322002 @default.
• W2218348537 hasConceptScore W2218348537C203014093 @default.
• W2218348537 hasConceptScore W2218348537C2522874641 @default.
• W2218348537 hasConceptScore W2218348537C2776408679 @default.
• W2218348537 hasConceptScore W2218348537C2776455275 @default.
• W2218348537 hasConceptScore W2218348537C2776461080 @default.
• W2218348537 hasConceptScore W2218348537C2776999253 @default.
• W2218348537 hasConceptScore W2218348537C2777391703 @default.
• W2218348537 hasConceptScore W2218348537C2779306644 @default.
• W2218348537 hasConceptScore W2218348537C2780040827 @default.
• W2218348537 hasConceptScore W2218348537C71924100 @default.
• W2218348537 hasConceptScore W2218348537C90924648 @default.
• W2218348537 hasIssue "7" @default.
• W2218348537 hasLocation W22183485371 @default.
• W2218348537 hasOpenAccess W2218348537 @default.
• W2218348537 hasPrimaryLocation W22183485371 @default.
• W2218348537 hasRelatedWork W1683920179 @default.
• W2218348537 hasRelatedWork W2000851328 @default.
• W2218348537 hasRelatedWork W2003677761 @default.
• W2218348537 hasRelatedWork W2029565038 @default.
• W2218348537 hasRelatedWork W2049494201 @default.
• W2218348537 hasRelatedWork W2079572247 @default.
• W2218348537 hasRelatedWork W2082200384 @default.
• W2218348537 hasRelatedWork W2166034731 @default.
• W2218348537 hasRelatedWork W2330453659 @default.
• W2218348537 hasRelatedWork W2579753162 @default.
• W2218348537 hasVolume "13" @default.
• W2218348537 isParatext "false" @default.
• W2218348537 isRetracted "false" @default.
• W2218348537 magId "2218348537" @default.
• W2218348537 workType "article" @default.